Org 28611

Org 28611
Legal status
Legal status	CA: Schedule II ; DE: NpSG (Industrial and scientific use only) ; UK: Under Psychoactive Substances Act ;
Identifiers
	IUPAC name [1-(cyclohexylmethyl)-7-methoxyindol-3-yl]-[(3S)-3,4-dimethylpiperazin-1-yl]methanone;
CAS Number	639068-99-8 ;
PubChem CID	10091392;
ChemSpider	8266929 ;
UNII	1U7V49NTQG;
ChEMBL	ChEMBL1209709 ;
Chemical and physical data
Formula	C23H33N3O2
Molar mass	383.536 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc3cccc(c13)c(C(=O)N(CC2C)CCN2C)cn1CC4CCCCC4;
	InChI InChI=1S/C23H33N3O2/c1-17-14-25(13-12-24(17)2)23(27)20-16-26(15-18-8-5-4-6-9-18)22-19(20)10-7-11-21(22)28-3/h7,10-11,16-18H,4-6,8-9,12-15H2,1-3H3/t17-/m0/s1 ; Key:ONXJNAIZJKLJGA-KRWDZBQOSA-N ;
	(what is this?) (verify)

Org 28611 (SCH-900,111) is a drug developed by Organon International which acts as a potent cannabinoid receptor full agonist at both the CB₁ and CB₂ receptors. It was developed with the aim of finding a water-soluble cannabinoid agonist suitable for intravenous use as an analgesic,[1] and while it achieved this aim and has progressed as far as Phase II clinical trials in humans as both a sedative and an analgesic, results against the comparison drugs (midazolam and morphine respectively) were not particularly favourable in initial testing.[2][3]

References

Adam, J. M.; et al. (2010). "Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists". MedChemComm. Royal Society of Chemistry. 1: 54. doi:10.1039/c0md00022a.
Zuurman L, Passier PC, de Kam M, Kleijn HJ, Cohen AF, van Gerven JM (August 2009). "Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers". Journal of Psychopharmacology (Oxford, England). 23 (6): 633–44. doi:10.1177/0269881108091551. PMID 18635703. S2CID 43609218.
A Comparison of Analgesic Efficacy Between a Single Dose of ORG 28611, Morphine, and Placebo After Dental Impaction Surgery

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.